Viridian Therapeutics, Inc. (VRDN) fell 8.56% to trade at $21.97, down $2.06, after announcing a public offering of 11,425,000 shares priced at $22.00 per share, with gross proceeds expected to be approximately $251.35 million.
The company granted underwriters a 30-day option to purchase an additional 1,713,750 shares at the same price. Viridian intends to use the proceeds to fund its commercial launch activities for veligrotug and VRDN-003, support R&D efforts, and for general corporate purposes.
On Wednesday, VRDN opened at $22.45, hit a high of $22.90, and a low of $21.50, compared to a previous close of $24.03 on the NASDAQ. Trading volume surged above average levels. The stock's 52-week range is $19.00 - $38.75.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.